BridgeMD
New treatment option for Schizophrenia
Official title Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease
ClinicalTrials.gov ID: NCT04946916
What this study is testing
- What it's testing
- The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 to 80
You may be able to join if
- haven given written consent Participants with psychiatric conditions:
- Schizophrenia (DSM-V criteria) with or without cognitive involution
- Bipolar disorder (DSM-V criteria) with or without cognitive involution Participants with neurodegenerative disease:
- probable or definite FTD (Rascovsky criteria 2011)
- Biological Alzheimer's disease with typical CSF (NIA-AA 2011)
You likely can't join if
- Uninterviewable patient and/or missing history
- History of recent or previous head trauma with loss of consciousness
- History of ischemic or hemorrhagic stroke
- Chronic alcoholism / chronic drug use
- Progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy
- Age \< 45 years
See the full eligibility criteria
- haven given written consent Participants with psychiatric conditions:
- Schizophrenia (DSM-V criteria) with or without cognitive involution
- Bipolar disorder (DSM-V criteria) with or without cognitive involution Participants with neurodegenerative disease:
- probable or definite FTD (Rascovsky criteria 2011)
- Biological Alzheimer's disease with typical CSF (NIA-AA 2011)
- Uninterviewable patient and/or missing history
- History of recent or previous head trauma with loss of consciousness
- History of ischemic or hemorrhagic stroke
- Chronic alcoholism / chronic drug use
- Progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy
- Age \< 45 years
- Age \> 80 years
- Electroconvulsive therapy for less than 6 months
The study team makes the final eligibility decision.
Where it's taking place
- Bron, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bron, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.